Approval · Notice of Compliance 30771 · 2023
THYROGEN: Notice of Compliance 30771
Issued May 17, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30771
- Date
- May 17, 2023
- Company
- Sanofi Genzyme, A Division Of Sanofi-Aventis Canada IncToronto, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Package Insert update
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| THYROGEN | Not yet assigned | — |
Medicinal ingredients
- THYROTROPIN ALFA 1.1 MG per VIAL